bioAffinity Technologies President and CEO Maria Zannes will present the Company’s recent advancements in commercializing CyPath® Lung, a noninvasive test to diagnose early stage lung cancer and meet with investors at H.C. Wainwright & Company’s 23rd Annual Global Investment Conference, which is being held as a virtual event from September 13-15, 2021. The daily format includes corporate presentations, investor one-on-one meetings, topical presentations by keynote speakers and virtual evening events to encourage informal interaction amongst conference participants. The annual conference is a “must see” event for institutional investors of all types, private equity firms, venture capitalists, industry executives and business development executives.
